Inhibiting interaction between the HIF-1ALPHA and p300/CBP with hydrogen bond surrogate-based helices
US9399666B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 18, 2009 |
| Grant date | Jul 26, 2016 |
| Priority date | — |
| Expiry date | Sep 18, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to peptides having one or more stable, internally constrained α-helices, and that include a sequence that mimics at least a portion of the C-terminal transactivation domain of HIF-1α. Also disclosed are pharmaceutical compositions containing these peptides and methods of using these peptides, for example to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF-1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, decrease cell survival and/or proliferation, and identify potential ligands of CREB-binding protein and/or p300.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.